Addressing High Costs of Clinical Trials Associated with Personalised Neoantigen Therapies to Overcome Them & Further Therapies into the Clinic
- Identifying the key cost drivers in personalised neoantigen clinical trials, including individualised vaccine manufacturing, patient-specific sequencing, and complex logistics
- Exploring strategies to reduce expenses, such as standardising workflows, utilising modular manufacturing platforms, and leveraging digital tools for trial management
- Highlighting how cost optimisation can accelerate patient access, improve trial feasibility